Core Viewpoint - Chongqing Huason Pharmaceutical Co., Ltd. has received approval for a change in its production license for special medical purpose formula foods, expanding its product range [1][4]. Group 1: License Change - The company has obtained a new production license for special medical purpose formula foods, which includes an expanded range of food categories [1]. - The updated license is issued by the Chongqing Municipal Market Supervision Administration [1]. Group 2: Product Information - The company's Gan Yimei liquid formula food is designed for patients over 10 years old with strict fat restrictions and digestive absorption disorders, featuring a scientific formula with 0 fat and 0 fiber [2]. - The product provides a high carbohydrate energy ratio of 87%, ensuring quick energy supply with minimal digestive burden, and includes essential vitamins and minerals for balanced nutrition [2]. - It is suitable for nutritional support in conditions such as acute pancreatitis and short bowel syndrome, and can also be used as a standardized liquid diet before colonoscopy [2]. Group 3: Market Potential - The global market for special medical purpose formula foods is estimated to reach $24.8 billion in 2024, with a projected compound annual growth rate (CAGR) of 5.13%, reaching $33.49 billion by 2030 [2]. - In China, the market size for special medical purpose formula foods is estimated at RMB 16.4 billion (approximately $2.27 billion) in 2024, holding the largest revenue share in the Asia-Pacific region, accounting for 9.15% of the global market [2]. - The Chinese market is expected to grow at a CAGR of 6.58%, reaching RMB 24 billion (approximately $3.33 billion) by 2030, indicating significant potential due to low current clinical usage rates compared to developed countries [2].

Group 1 - The core point of the article is that Chongqing Huasen Pharmaceutical Co., Ltd. has received a production license for special medical purpose formula foods, which supports the production of its product "Ganyimei®" [1] - The product "Ganyimei®" is designed for individuals over 10 years old who require strict fat restrictions and have digestive absorption disorders, featuring a scientific formula with 0 fat and 0 fiber, primarily composed of carbohydrates with a high energy supply ratio of 87% [1] - The product is applicable in various scenarios, including nutritional support for acute pancreatitis, short bowel syndrome, and gastrointestinal function damage, as well as standardized liquid diets before colonoscopy [1] Group 2 - According to Grand View Research, the global special medical food market is projected to reach $24.8 billion in 2024 and grow at a compound annual growth rate (CAGR) of 5.13% to $33.49 billion by 2030 [2] - The Chinese market is expected to be approximately 16.4 billion RMB in 2024, accounting for 9.15% of the global market share, with a projected CAGR of 6.58% to reach 24 billion RMB by 2030 [2] - The clinical usage rate of special medical foods in China is currently much lower than in developed countries, indicating significant growth potential as health awareness and clinical nutritional support needs increase [2] - The production license change is a foundational step for the company to expand its special medical food business and is an important measure for enhancing its health industry layout [2]

证券代码：002907 证券简称：华森制药 公告编号：2025-090 重庆华森制药股份有限公司 关于公司特殊医学用途配方食品生产许可证 变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 近日，重庆华森制药股份有限公司（以下简称"公司"）收到重庆市市场监 督管理局核准签发的《特殊医学用途配方食品生产许可证》（许可证编号： SC12850000050231），本次变更主要涉及新增食品类别范围。具体情况如下： 一、变更后的《食品生产许可证》具体内容 公司已于 2025 年 11 月获得国家市场监督管理总局核准签发的《特殊医学用 途配方食品注册证书》，详情可查阅《关于公司获得特殊医学用途配方食品注册 证书的公告》（公告编号：2025-084）。 生 产 者 名 称：重庆华森制药股份有限公司 许 可 证 编 号：SC12850000050231 社 会 信 用 代 码：915002262038944463 生 产 地 址： 重庆市荣昌区昌州街道昌州大道东段 27 号（重庆市 荣昌区工业园区） 食 品 类 别：特殊医学用途配方食品；饮料 审 批 结 论：华森制 ...

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received a new drug production license from the Chongqing Municipal Drug Administration, which includes changes in entrusted production for the drug Empagliflozin tablets [1] Group 1: License Details - The license number issued is 渝20150018, which involves a reduction in entrusted production limited to drug registration applications [1] - The entrusted production reduction is for Empagliflozin tablets (10mg, 25mg) with the client being Youhua Pharmaceutical Technology Co., Ltd., and the production site located at No. 143, Banqiao Road, Changzhou Street, Rongchang District, Chongqing, valid until November 9, 2025 [1] - Additionally, there is new entrusted production for Empagliflozin tablets (National Drug Approval Numbers H20255257, H20255258) with the same client and production site, valid until March 2, 2026 [1]

证券代码：002907 证券简称：华森制药 公告编号：2025-089 | 企 | | | 名 | | 称：重庆华森制药股份有限公司 | | | | | 业 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 许 | 可 | | | | 号：渝 20150018 | | | | | | 证 | 编 | | | 社 | 会 | 信 | 用 | 代 | 码：915002262038944463 | | | | | | | | | | 分 | | | | | 码：AhzyBhzChDh | | | | | | 类 | | | | 注 | | | 地 | | 址：重庆市荣昌区工业园区 | | | | | 册 | | | | | | | | | | 人：游洪涛 | | | | 定 | | 代 | 表 | | | 企 | 业 | | | | 人：游洪涛 | | | | | | 负 | | | | 质 | 量 | | | | 人：邓林 | | | | | | 负 | 责 | | | 质 ...

Market Performance - The Chinese medicine sector rose by 0.35% on December 25, with Wanbangde leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] Top Gainers in Chinese Medicine Sector - Wanbangde (002082) closed at 13.42, up 10.00% with a trading volume of 221,500 shares and a transaction value of 286 million yuan [1] - ST Changyao (300391) closed at 1.53, up 5.52% with a trading volume of 469,000 shares and a transaction value of 71.61 million yuan [1] - Huasen Pharmaceutical (002907) closed at 15.57, up 4.01% with a trading volume of 62,100 shares and a transaction value of 96.15 million yuan [1] Market Trends and Capital Flow - The Chinese medicine sector experienced a net outflow of 130 million yuan from institutional investors, while retail investors saw a net inflow of 163 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Wanbangde had a net inflow of 30.98 million yuan from institutional investors, but a net outflow of 30.35 million yuan from retail investors [3] - Jiaying Pharmaceutical (002198) saw a net inflow of 16.25 million yuan from institutional investors, while retail investors had a net outflow of 9.67 million yuan [3] - Kangmei Pharmaceutical (600518) experienced a net inflow of 15.73 million yuan from institutional investors, with retail investors withdrawing 4.15 million yuan [3]

Group 1 - The core point of the article is that Huason Pharmaceutical has received a re-registration approval for its injectable omeprazole sodium, which is a significant product for the company [1][2] - The re-registration approval is valid until January 11, 2031, ensuring the product's continued production and sales [1][2] - The product is included in the national medical insurance and essential drug catalog, and is recommended in multiple clinical guidelines [1] Group 2 - On December 24, the stock price of Huason Pharmaceutical closed at 14.97 yuan, with a slight decrease of 0.13% [1] - The trading volume was 18,600 shares, with a total transaction amount of 27.83 million yuan [1] - The net capital flow showed a net outflow of 141.66 thousand yuan from institutional investors and 125.62 thousand yuan from speculative funds, while retail investors had a net inflow of 267.28 thousand yuan [1][2]

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received approval from the Chongqing Municipal Drug Administration for the re-registration of its product, injectable omeprazole sodium, indicating a significant regulatory milestone for the company [1] Group 1: Product Approval - The approval includes indications for treating various conditions such as bleeding from peptic ulcers and anastomotic ulcers [1] - It is also indicated for acute gastric mucosal damage due to stress and acute gastric mucosal injury caused by non-steroidal anti-inflammatory drugs [1] - The product serves as an alternative therapy for conditions where oral therapy is not suitable, including duodenal ulcers, gastric ulcers, gastroesophageal reflux disease, and Zollinger-Ellison syndrome [1]

重庆华森制药股份有限公司 证券代码：002907 证券简称：华森制药 公告编号：2025-088 注射用奥美拉唑钠是上消化道出血经典用药，临床必需；为国家医保目录产 品，获多项指南共识推荐；是唯一进入国家基药目录的质子泵抑制剂，应用范围 广。 关于公司收到药品再注册批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监 督管理局（以下简称"市药监局"）核准签发的关于公司产品注射用奥美拉唑钠 的《药品再注册批准通知书》。现将相关情况公告如下： 一、《药品再注册批准通知书》主要信息 （一）注射用奥美拉唑钠 | 药 | 品 | 通 | | 用 | 名 | 称：注射用奥美拉唑钠 | | --- | --- | --- | --- | --- | --- | --- | | 英 | 文 | 名 | / | 拉 | 丁 | 名：Omeprazole Sodium for Injection | | 受 | | | 理 | | | 号：CYHZ2547652 渝 | | 通 | 知 | | 书 | ...

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received approval from the Chongqing Municipal Drug Administration for the re-registration of its injectable omeprazole sodium product, indicating a significant regulatory milestone for the company [1] Group 1: Product Approval - The product is indicated for several conditions, including bleeding from peptic ulcers and anastomotic ulcers [1] - It is also approved for acute gastric mucosal damage due to stress and acute gastric mucosal injury caused by non-steroidal anti-inflammatory drugs [1] - The drug serves as an alternative therapy for conditions where oral therapy is not suitable, such as duodenal ulcers, gastric ulcers, gastroesophageal reflux disease, and Zollinger-Ellison syndrome [1]